Matthew Galsky

Publications

• Phase 2 Trial of the Topoisomerase II Inhibitor, Amrubicin, As Second-line Therapy in Patients with Metastatic Urothelial Carcinoma
  Cancer Chemotherapy and Pharmacology. Oct, 2015  |   Pubmed ID: 26464352
• Neoadjuvant Dasatinib for Muscle-invasive Bladder Cancer with Tissue Analysis of Biologic Activity
  Urologic Oncology. Sep, 2015  |   Pubmed ID: 26362343
• A Robust Blood Gene Expression-based Prognostic Model for Castration-resistant Prostate Cancer
  BMC Medicine. 2015  |   Pubmed ID: 26297150
• Reporting Quality of Abstracts in Phase III Clinical Trials of Systemic Therapy in Metastatic Solid Malignancies
  Trials. 2015  |   Pubmed ID: 26253548
• Concurrent Diabetes Mellitus May Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer
  Frontiers in Oncology. 2015  |   Pubmed ID: 26125012
• Neoadjuvant Chemotherapy in the Management of Muscle-invasive Bladder Cancer: Bridging the Gap Between Evidence and Practice
  The Urologic Clinics of North America. May, 2015  |   Pubmed ID: 25882560
• Comparative Effectiveness of Gemcitabine Plus Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin As Neoadjuvant Therapy for Muscle-invasive Bladder Cancer
  Cancer. Aug, 2015  |   Pubmed ID: 25872978
• The Landscape of Precision Cancer Medicine Clinical Trials in the United States
  Cancer Treatment Reviews. May, 2015  |   Pubmed ID: 25864024
• First-line Treatment of Metastatic Disease: Cisplatin-ineligible Patients
  Hematology/oncology Clinics of North America. Apr, 2015  |   Pubmed ID: 25836938
• Clinical Trial Awareness: Changes over Time and Sociodemographic Disparities
  Clinical Trials (London, England). Jun, 2015  |   Pubmed ID: 25673636
• A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
  Cancer Cell. Feb, 2015  |   Pubmed ID: 25670080
• The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care
  The Journal of Urology. Jul, 2015  |   Pubmed ID: 25623748
• Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease
  The Journal of Urology. Jul, 2015  |   Pubmed ID: 25623747
• Kidney Cancer: Systemic Therapy--differentiating the Achievable from the Achieved
  Nature Reviews. Urology. Mar, 2015  |   Pubmed ID: 25600095
• Elevated Circulating Tissue Inhibitor of Metalloproteinase 1 (TIMP-1) Levels Are Associated with Neuroendocrine Differentiation in Castration Resistant Prostate Cancer
  The Prostate. May, 2015  |   Pubmed ID: 25560638
• Survival of Patients with Stage IV Lung Cancer with Diabetes Treated with Metformin
  American Journal of Respiratory and Critical Care Medicine. Feb, 2015  |   Pubmed ID: 25522257
• How I Treat Bladder Cancer in Elderly Patients
  Journal of Geriatric Oncology. Jan, 2015  |   Pubmed ID: 25482022
• Complete Response As an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma
  Clinical Genitourinary Cancer. Apr, 2015  |   Pubmed ID: 25458370
• Geographic Accessibility to Clinical Trials for Advanced Cancer in the United States
  JAMA Internal Medicine. Feb, 2015  |   Pubmed ID: 25437434
• Clinical Decision Making in Castration-resistant Prostate Cancer According to Baseline Prostate-specific Antigen: Are We Measuring Disease Burden or Disease Biology?
  European Urology. Feb, 2015  |   Pubmed ID: 25220371
• Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to Move Research Forward
  Urologic Oncology. Feb, 2015  |   Pubmed ID: 25065704
• Cytotoxic Chemotherapy in the Contemporary Management of Metastatic Castration-resistant Prostate Cancer (mCRPC)
  BJU International. Jul, 2015  |   Pubmed ID: 25046451
• A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
  European Urology. Jan, 2015  |   Pubmed ID: 24841777
• Repurposing of Bisphosphonates for the Prevention and Therapy of Nonsmall Cell Lung and Breast Cancer
  Proceedings of the National Academy of Sciences of the United States of America. Dec, 2014  |   Pubmed ID: 25453078
• Biomarkers for Bladder Cancer Management: Present and Future
  American Journal of Clinical and Experimental Urology. 2014  |   Pubmed ID: 25374904
• Is Prostate Cancer Changing?: Evolving Patterns of Metastatic Castration-resistant Prostate Cancer
  Cancer. Mar, 2014  |   Pubmed ID: 25302607
• Use of Crowdsourcing for Cancer Clinical Trial Development
  Journal of the National Cancer Institute. Oct, 2014  |   Pubmed ID: 25217580
• Adult Cancer Clinical Trials That Fail to Complete: an Epidemic?
  Journal of the National Cancer Institute. Sep, 2014  |   Pubmed ID: 25190726
• Cisplatin Vs. Carboplatin-based Chemoradiotherapy in Patients >65 Years of Age with Stage III Non-small Cell Lung Cancer
  Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology. Aug, 2014  |   Pubmed ID: 25150635
• Rethinking Cancer Clinical Trials for the Future
  Future Oncology (London, England). 2014  |   Pubmed ID: 25145425
• Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide As First-line Therapy in Patients with Metastatic Urothelial Carcinoma
  The Oncologist. Sep, 2014  |   Pubmed ID: 25052451
• Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma
  Clinical Genitourinary Cancer. Dec, 2014  |   Pubmed ID: 25035282
• Phase Ib Study of Dovitinib in Combination with Gemcitabine Plus Cisplatin or Gemcitabine Plus Carboplatin in Patients with Advanced Solid Tumors
  Cancer Chemotherapy and Pharmacology. Sep, 2014  |   Pubmed ID: 25023489
• New Drugs and Treatment Strategies in Prostate Cancer
  Clinical Advances in Hematology & Oncology : H&O. Jan, 2014  |   Pubmed ID: 25000316
• Mind the Gap: Efficacy Versus Effectiveness and Pivotal Prostate Cancer Clinical Trial Demographics
  Cancer. Oct, 2014  |   Pubmed ID: 24965362
• Current Approaches to the Management of Bladder Cancer in Older Patients
  American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting. 2014  |   Pubmed ID: 24857110
• Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis
  American Journal of Clinical Oncology. May, 2014  |   Pubmed ID: 24824144
• T2 Muscle-invasive Bladder Cancer
  Seminars in Oncology. Apr, 2014  |   Pubmed ID: 24787300
• A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2014  |   Pubmed ID: 24727324
• Targeting Vascular Endothelial Growth Factor Receptor Signaling in Renal Cancer: the Sooner the Better?
  European Urology. Nov, 2014  |   Pubmed ID: 24631407
• Safety and Efficacy of Addition of VEGFR and EGFR-family Oral Small-molecule Tyrosine Kinase Inhibitors to Cytotoxic Chemotherapy in Solid Cancers: a Systematic Review and Meta-analysis of Randomized Controlled Trials
  Cancer Treatment Reviews. Jun, 2014  |   Pubmed ID: 24629273
• Impact of Prednisone on Toxicities and Survival in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Meta-analysis of Randomized Clinical Trials
  Critical Reviews in Oncology/hematology. Jun, 2014  |   Pubmed ID: 24500033
• Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer
  European Urology. Aug, 2014  |   Pubmed ID: 24433812
• Cisplatin-ineligible and Chemotherapy-ineligible Patients Should Be the Focus of New Drug Development in Patients with Advanced Bladder Cancer
  Clinical Genitourinary Cancer. Apr, 2014  |   Pubmed ID: 24355418
• Prognostic Risk Stratification Derived from Individual Patient Level Data for Men with Advanced Penile Squamous Cell Carcinoma Receiving First-line Systemic Therapy
  Urologic Oncology. May, 2014  |   Pubmed ID: 24332646
• Adverse Event Reporting in Cancer Clinical Trial Publications
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jan, 2014  |   Pubmed ID: 24323037
• Radiographic Progression by Prostate Cancer Working Group (PCWG)-2 Criteria As an Intermediate Endpoint for Drug Development in Metastatic Castration-resistant Prostate Cancer
  BJU International. Dec, 2014  |   Pubmed ID: 24298897
• Six-month Progression-free Survival As the Primary Endpoint to Evaluate the Activity of New Agents As Second-line Therapy for Advanced Urothelial Carcinoma
  Clinical Genitourinary Cancer. Apr, 2014  |   Pubmed ID: 24220220
• A Nomogram Including Baseline Prognostic Factors to Estimate the Activity of Second-line Therapy for Advanced Urothelial Carcinoma
  BJU International. May, 2014  |   Pubmed ID: 24219029
• Posttreatment Prognostic Nomogram for Patients with Metastatic Urothelial Cancer Completing First-line Cisplatin-based Chemotherapy
  Urologic Oncology. Jan, 2014  |   Pubmed ID: 24055428
• Metastatic Renal Cancer: Better Never Than Late
  European Urology. Jun, 2014  |   Pubmed ID: 23954087
• Pulmonary Complications with the Use of MTOR Inhibitors in Targeted Cancer Therapy: a Systematic Review and Meta-analysis
  Targeted Oncology. Sep, 2014  |   Pubmed ID: 23852656
• Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor-κB Ligand Inhibitors in Patients with Advanced Prostate Cancer
  European Urology. Feb, 2014  |   Pubmed ID: 23706567
• Association of the Charlson Comorbidity Index and Hypertension with Survival in Men with Metastatic Castration-resistant Prostate Cancer
  Urologic Oncology. Jan, 2014  |   Pubmed ID: 23685020
• Metabolic Complications with the Use of MTOR Inhibitors for Cancer Therapy
  Cancer Treatment Reviews. Feb, 2014  |   Pubmed ID: 23684373
• Cisplatin-based Combination Chemotherapy in Septuagenarians with Metastatic Urothelial Cancer
  Urologic Oncology. Jan, 2014  |   Pubmed ID: 23428534
• Risk of Hematologic Toxicities in Patients with Solid Tumors Treated with Everolimus: a Systematic Review and Meta-analysis
  Critical Reviews in Oncology/hematology. Oct, 2013  |   Pubmed ID: 23830806
• Glasgow Prognostic Score As a Prognostic Factor in Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel-based Chemotherapy
  Clinical Genitourinary Cancer. Dec, 2013  |   Pubmed ID: 23816526
• Impact of Response to Prior Chemotherapy in Patients with Advanced Urothelial Carcinoma Receiving Second-line Therapy: Implications for Trial Design
  Clinical Genitourinary Cancer. Dec, 2013  |   Pubmed ID: 23800847
• Tumour Angiogenesis: an Elusive Target in Castration-resistant Prostate Cancer
  The Lancet. Oncology. Jul, 2013  |   Pubmed ID: 23742876
• Nomogram for Predicting Survival in Patients with Unresectable And/or Metastatic Urothelial Cancer Who Are Treated with Cisplatin-based Chemotherapy
  Cancer. Aug, 2013  |   Pubmed ID: 23720216
• Relationship Between 6- and 9-month Progression-free Survival and Overall Survival in Patients with Metastatic Urothelial Cancer Treated with First-line Cisplatin-based Chemotherapy
  Cancer. Aug, 2013  |   Pubmed ID: 23720197
• A New Approach to Second-line Therapy for Urothelial Cancer?
  The Lancet. Oncology. Jul, 2013  |   Pubmed ID: 23706984
• The Impact of Gender on Outcomes in Patients with Metastatic Urothelial Carcinoma
  Clinical Genitourinary Cancer. Sep, 2013  |   Pubmed ID: 23673281
• Intermittent Androgen-deprivation Therapy in Prostate Cancer: a Critical Review Focused on Phase 3 Trials
  European Urology. Nov, 2013  |   Pubmed ID: 23628492
• Advances in the Management of Muscle-invasive Bladder Cancer Through Risk Prediction, Risk Communication, and Novel Treatment Approaches
  Clinical Advances in Hematology & Oncology : H&O. Feb, 2013  |   Pubmed ID: 23598909
• Metabolic and Toxicological Considerations of Newly Approved Prostate Cancer Drugs
  Expert Opinion on Drug Metabolism & Toxicology. Jul, 2013  |   Pubmed ID: 23581700
• Critical Analysis of Contemporary Clinical Research in Muscle-invasive and Metastatic Urothelial Cancer: a Report from the Bladder Cancer Advocacy Network Clinical Trials Working Group
  Cancer. Jun, 2013  |   Pubmed ID: 23456777
• Risk of Hematologic Toxicities in Cancer Patients Treated with Sunitinib: a Systematic Review and Meta-analysis
  Cancer Treatment Reviews. Nov, 2013  |   Pubmed ID: 23455076
• Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin As First-line Therapy for Advanced Urothelial Carcinoma
  Clinical Genitourinary Cancer. Sep, 2013  |   Pubmed ID: 23332638
• Venous Thromboembolic Events with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: a Systematic Review and Meta-analysis of Randomized Clinical Trials
  Critical Reviews in Oncology/hematology. Jul, 2013  |   Pubmed ID: 23317774
• A Prognostic Model for Metastatic Renal-cell Carcinoma
  The Lancet. Oncology. Feb, 2013  |   Pubmed ID: 23312462
• Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy in the United States: a SEER Analysis
  World Journal of Urology. Dec, 2013  |   Pubmed ID: 23223962
• Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: a Retrospective Analysis of Pooled, Prospective Phase 2 Trials
  European Urology. Apr, 2013  |   Pubmed ID: 23206856
• ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma-neoadjuvant and Adjuvant Settings
  European Urology. Jan, 2013  |   Pubmed ID: 22917984
• Trends and Variations in Utilization of Nephron-sparing Procedures for Stage I Kidney Cancer in the United States
  World Journal of Urology. Oct, 2013  |   Pubmed ID: 22622394
• Efficacy of Docetaxel-based Chemotherapy Following Ketoconazole in Metastatic Castration-resistant Prostate Cancer: Implications for Prior Therapy in Clinical Trials
  Urologic Oncology. Nov, 2013  |   Pubmed ID: 22552048
• The Follicle-stimulating Hormone Receptor: a Novel Target in Genitourinary Malignancies
  Urologic Oncology. Nov, 2013  |   Pubmed ID: 22513137
• Summary of the 6th Annual Bladder Cancer Think Tank: New Directions in Urologic Research
  Urologic Oncology. Oct, 2013  |   Pubmed ID: 22300756
• New Developments in Urothelial Cancer
  American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting. 2012  |   Pubmed ID: 24451754
• Emerging Personalized Approaches for the Management of Advanced Urothelial Carcinoma
  Expert Review of Anticancer Therapy. Dec, 2012  |   Pubmed ID: 23253220
• Gemcitabin, Cisplatin Und Sunitinib Für Metastasierendem Urothelial Karzinom Und Als Präoperative Therapie Für Muskel-invasiven Blasenkrebs
  Clinical Genitourinary Cancer. Dec, 2012  |   Pubmed ID: 23228446
• Risk of Venous Thromboembolism in Patients with Cancer Treated with Cisplatin: a Systematic Review and Meta-analysis
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Dec, 2012  |   Pubmed ID: 23150697
• Arterial Thromboembolism in Cancer Patients Treated with Cisplatin: a Systematic Review and Meta-analysis
  Journal of the National Cancer Institute. Dec, 2012  |   Pubmed ID: 23093559
• A Whole-blood RNA Transcript-based Prognostic Model in Men with Castration-resistant Prostate Cancer: a Prospective Study
  The Lancet. Oncology. Nov, 2012  |   Pubmed ID: 23059047
• Neutropenia As a Potential Pharmacodynamic Marker for Docetaxel-based Chemotherapy in Men with Metastatic Castration-resistant Prostate Cancer
  Clinical Genitourinary Cancer. Dec, 2012  |   Pubmed ID: 23000202
• Targeting the Androgen Receptor Signalling Axis in Castration-resistant Prostate Cancer (CRPC)
  BJU International. Dec, 2012  |   Pubmed ID: 22985411
• Editorial Comment
  The Journal of Urology. Oct, 2012  |   Pubmed ID: 22901587
• Antiangiogenic Treatment in Metastatic Urothelial Cancer
  The Lancet. Oncology. Aug, 2012  |   Pubmed ID: 22819171
• Phase II Trial of Concurrent Sunitinib and Image-guided Radiotherapy for Oligometastases
  PloS One. 2012  |   Pubmed ID: 22761653
• Prevalence and Characteristics of Patients with Metastatic Cancer Who Receive No Anticancer Therapy
  Cancer. Dec, 2012  |   Pubmed ID: 22707387
• Is Adjunctive Systemic Chemotherapy After Cystectomy for T2N+ Disease of Therapeutic Benefit?
  The Journal of Urology. Aug, 2012  |   Pubmed ID: 22704119
• Eine Systematische Überprüfung Der Neoadjuvanten Und Adjuvanten Chemotherapie Für Muskel-invasiven Blasenkrebs
  European Urology. Sep, 2012  |   Pubmed ID: 22677572
• Targeting the FOXO1/KLF6 Axis Regulates EGFR Signaling and Treatment Response
  The Journal of Clinical Investigation. Jul, 2012  |   Pubmed ID: 22653055
• Trends in the Use of Cytoreductive Nephrectomy in the United States
  Clinical Genitourinary Cancer. Sep, 2012  |   Pubmed ID: 22651971
• Treatment-related Mortality with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients with Advanced Solid Tumors: a Meta-analysis
  Cancer Treatment Reviews. Nov, 2012  |   Pubmed ID: 22651902
• The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer
  The Journal of Urology. Jul, 2012  |   Pubmed ID: 22578722
• Clinical Development of Novel Therapeutics for Castration-resistant Prostate Cancer: Historic Challenges and Recent Successes
  CA: a Cancer Journal for Clinicians. Sep-Oct, 2012  |   Pubmed ID: 22535487
• Ability of C-reactive Protein to Complement Multiple Prognostic Classifiers in Men with Metastatic Castration Resistant Prostate Cancer Receiving Docetaxel-based Chemotherapy
  BJU International. Dec, 2012  |   Pubmed ID: 22520631
• Novel Molecular Targets for the Therapy of Urothelial Carcinoma
  Expert Opinion on Therapeutic Targets. May, 2012  |   Pubmed ID: 22510032
• Overcoming Castration Resistance in Prostate Cancer
  Current Opinion in Urology. May, 2012  |   Pubmed ID: 22472508
• Objective Measures of Physical Functional Capacity Warrant Exploration to Complement or Replace the Subjective Physician Estimated Performance Status
  American Journal of Clinical Oncology. Apr, 2012  |   Pubmed ID: 22433994
• Editorial Comment
  The Journal of Urology. May, 2012  |   Pubmed ID: 22425108
• Association of Rash with Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination with Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer
  Clinical Genitourinary Cancer. Mar, 2012  |   Pubmed ID: 22340631
• Phase 2 Study of Neoadjuvant Docetaxel Plus Bevacizumab in Patients with High-risk Localized Prostate Cancer: a Prostate Cancer Clinical Trials Consortium Trial
  Cancer. Oct, 2012  |   Pubmed ID: 22282219
• Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients with Urothelial Cancer
  Clinical Genitourinary Cancer. Mar, 2012  |   Pubmed ID: 22130294
• Target-specific, Histology-independent, Randomized Discontinuation Study of Lapatinib in Patients with HER2-amplified Solid Tumors
  Investigational New Drugs. Apr, 2012  |   Pubmed ID: 20857170
• Multicenter Phase II Trial of the Heat Shock Protein 90 Inhibitor, Retaspimycin Hydrochloride (IPI-504), in Patients with Castration-resistant Prostate Cancer
  Urology. Sep, 2011  |   Pubmed ID: 21762967
• Role of American Society of Clinical Oncology in Low- and Middle-income Countries
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2011  |   Pubmed ID: 21709190
• Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-based Chemotherapy
  Clinical Genitourinary Cancer. Sep, 2011  |   Pubmed ID: 21700509
• Clinical Development of Cabazitaxel for the Treatment of Castration-resistant Prostate Cancer
  Clinical Medicine Insights. Oncology. 2011  |   Pubmed ID: 21695098
• Treatment of Patients with Metastatic Urothelial Cancer "unfit" for Cisplatin-based Chemotherapy
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jun, 2011  |   Pubmed ID: 21555688
• A Consensus Definition of Patients with Metastatic Urothelial Carcinoma Who Are Unfit for Cisplatin-based Chemotherapy
  The Lancet. Oncology. Mar, 2011  |   Pubmed ID: 21376284
• Randomized Phase II Trial of Single-agent Amrubicin or Topotecan As Second-line Treatment in Patients with Small-cell Lung Cancer Sensitive to First-line Platinum-based Chemotherapy
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jan, 2011  |   Pubmed ID: 21135284
• Azacitidine Favorably Modulates PSA Kinetics Correlating with Plasma DNA LINE-1 Hypomethylation in Men with Chemonaïve Castration-resistant Prostate Cancer
  Urologic Oncology. Nov-Dec, 2011  |   Pubmed ID: 19959380
• Bladder Cancer: Current Management and Opportunities for a Personalized Approach
  The Mount Sinai Journal of Medicine, New York. Nov-Dec, 2010  |   Pubmed ID: 21105122
• Cabazitaxel
  Nature Reviews. Drug Discovery. Sep, 2010  |   Pubmed ID: 20811375
• First-line Systemic Therapy Trials for Advanced Transitional-cell Carcinoma of the Urothelium: Should We Stop Separating Cisplatin-eligible and -ineligible Patients?
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Sep, 2010  |   Pubmed ID: 20644092
• Second-line Systemic Therapy and Emerging Drugs for Metastatic Transitional-cell Carcinoma of the Urothelium
  The Lancet. Oncology. Sep, 2010  |   Pubmed ID: 20537950
• Bladder Cancer: Advances in Treatment and Research
  Clinical Advances in Hematology & Oncology : H&O. Apr, 2010  |   Pubmed ID: 20505645
• Suggestions for Regulatory Agency Approval of Second-line Systemic Therapy for Metastatic Transitional Cell Carcinoma
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2010  |   Pubmed ID: 20159797
• Target-specific Randomized Discontinuation Trial Design: a Novel Approach in Molecular Therapeutics
  Investigational New Drugs. Apr, 2010  |   Pubmed ID: 19262991
• Utility of [18F]2-fluoro-2-deoxyglucose-PET in Sporadic and Tuberous Sclerosis-associated Lymphangioleiomyomatosis
  Chest. Sep, 2009  |   Pubmed ID: 19349386
• Patient Selection for Phase II Trials
  American Journal of Clinical Oncology. Apr, 2009  |   Pubmed ID: 19346816
• Trial Design for Metastatic Castration-resistant Prostate Cancer
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Jul, 2008  |   Pubmed ID: 18640946
• Phase I Trial of the Prostate-specific Membrane Antigen-directed Immunoconjugate MLN2704 in Patients with Progressive Metastatic Castration-resistant Prostate Cancer
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. May, 2008  |   Pubmed ID: 18362364
• Current Optimal Chemotherapy for Advanced Urothelial Cancer
  Expert Review of Anticancer Therapy. Jan, 2008  |   Pubmed ID: 18095883
• Roman-Agenten Für Muskel-invasiv Und Erweiterte Urothelial Krebs
  BJU International. Apr, 2008  |   Pubmed ID: 18005203
• Germ-cell Tumors
  The New England Journal of Medicine. Oct, 2007  |   Pubmed ID: 17969229
• Neoadjuvante Therapie Gefolgt Von Prostatektomie Für Klinisch Lokalisierten Prostatakrebs
  Cancer. Dec, 2007  |   Pubmed ID: 17941029
• Outcomes and Prognosis in Advanced Renal Cell Carcinoma
  Expert Review of Anticancer Therapy. Jun, 2007  |   Pubmed ID: 17555394
• Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract
  Urology. Feb, 2007  |   Pubmed ID: 17320659
• High-dose Bicalutamide After Radiotherapy for Locally Advanced Prostate Cancer: a Standard of Care?
  Nature Clinical Practice. Urology. Mar, 2007  |   Pubmed ID: 17297500
• Phase II Trial of Dose-dense Doxorubicin Plus Gemcitabine Followed by Paclitaxel Plus Carboplatin in Patients with Advanced Urothelial Carcinoma and Impaired Renal Function
  Cancer. Feb, 2007  |   Pubmed ID: 17200962
• Phase II Trial of Pemetrexed As Second-line Therapy in Patients with Metastatic Urothelial Carcinoma
  Investigational New Drugs. Jun, 2007  |   Pubmed ID: 17146733
• Targeting Growth Factor and Antiangiogenic Pathways in Clear-cell Renal Cell Carcinoma: Rationale and Ongoing Trials
  Clinical Genitourinary Cancer. Dec, 2006  |   Pubmed ID: 17239282
• Problems with the Randomized Discontinuation Design
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Oct, 2006  |   Pubmed ID: 17008711
• Impact of Renal Impairment on Eligibility for Adjuvant Cisplatin-based Chemotherapy in Patients with Urothelial Carcinoma of the Bladder
  Cancer. Aug, 2006  |   Pubmed ID: 16773629
• Violaceous Exanthem As a Manifestation of Metastatic Prostate Cancer in Skin
  Urology. Feb, 2006  |   Pubmed ID: 16461102
• A Retrospective Evaluation of Second-line Chemotherapy Response in Hormone-refractory Prostate Carcinoma: Second Line Taxane-based Therapy After First-line Epothilone-B Analog Ixabepilone (BMS-247550) Therapy
  Cancer. Jan, 2006  |   Pubmed ID: 16329138
• The Integration of Chemotherapy and Surgery for Bladder Cancer
  Journal of the National Comprehensive Cancer Network : JNCCN. Jan, 2005  |   Pubmed ID: 19813322
• The Role of Taxanes in the Management of Bladder Cancer
  The Oncologist. Nov-Dec, 2005  |   Pubmed ID: 16314289
• Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-specific Antigen in Men with Hormone-refractory Prostate Cancer Treated with Chemotherapy
  Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. Jul, 2005  |   Pubmed ID: 16033836
• Bladder Cancer "adjuvant-lite": Tastes Great (works As Well) and Less Filling (less Toxic)?
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Aug, 2005  |   Pubmed ID: 15939919
• Multi-institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) with or Without Estramustine Phosphate in Patients with Progressive Castrate Metastatic Prostate Cancer
  Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. Mar, 2005  |   Pubmed ID: 15735119